Privately held Banner Life Sciences announces that the U.S. commercial launch of Bafiertam (monomethyl fumarate) for adults with relapsing forms of multiple sclerosis (MS) will commence on Tuesday, September 1.
Bafiertam is a bioequivalent to Biogen’s (NASDAQ:BIIB) top seller Tecfidera (dimethyl fumarate), a prodrug of monomethyl fumarate.
Biogen sued Banner for patent infringement aimed at blocking the med’s release but failed.
Tecfidera accounted for over 31% of the company’s Q1 revenue.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.